These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 7986587)

  • 41. Characterization of gp120 hydrolysis by IgA antibodies from humans without HIV infection.
    Planque S; Mitsuda Y; Taguchi H; Salas M; Morris MK; Nishiyama Y; Kyle R; Okhuysen P; Escobar M; Hunter R; Sheppard HW; Hanson C; Paul S
    AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1541-54. PubMed ID: 18160012
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons.
    Mazzoli S; Lopalco L; Salvi A; Trabattoni D; Lo Caputo S; Semplici F; Biasin M; Bl C; Cosma A; Pastori C; Meacci F; Mazzotta F; Villa ML; Siccardi AG; Clerici M
    J Infect Dis; 1999 Sep; 180(3):871-5. PubMed ID: 10438383
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1.
    Tay MZ; Kunz EL; Deal A; Zhang L; Seaton KE; Rountree W; Eudailey JA; Heptinstall J; McRaven MD; Matias E; McGuire E; Yates NL; Perez LG; Montefiori DC; Overman RG; Hope TJ; Shen X; Kalilani L; Fouda GG; Tomaras GD; Permar SR
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30700599
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibody reactivity to deletion mutants of the HIV-1 SF2 envelope.
    Back NK; Haigwood NL; de Wolf F; de Jongh BM; Goudsmit J
    Intervirology; 1991; 32(3):160-72. PubMed ID: 2040587
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins.
    Neurath AR; Jiang S; Strick N; Kolbe H; Kieny MP; Muchmore E; Girard M
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):813-23. PubMed ID: 1720628
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodies.
    Polonis VR; De Souza MS; Chanbancherd P; Chantakulkij S; Jugsudee A; Loomis-Price LD; Vancott TC; Garner R; Markowitz LE; Brown AE; Birx DL
    AIDS Res Hum Retroviruses; 2001 Jan; 17(1):69-79. PubMed ID: 11177385
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
    Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
    J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope.
    Davis D; Stephens DM; Carne CA; Lachmann PJ
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2609-17. PubMed ID: 7506300
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human immunodeficiency virus V3 peptide-reactive antibodies are present in normal HIV-negative sera.
    Metlas R; Trajkovic D; Srdic T; Veljkovic V; Colombatti A
    AIDS Res Hum Retroviruses; 1999 May; 15(7):671-7. PubMed ID: 10331446
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-V3 and anti-IgG antibodies of healthy individuals share complementarity structures.
    Metlas R; Trajkovic D; Srdic T; Veljkovic V; Colombatti A
    J Acquir Immune Defic Syndr; 1999 Aug; 21(4):266-70. PubMed ID: 10428103
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reactivity of AIDS patient sera with a peptide derived from HIV type 1NY5 glycoprotein 120 V3 loop and consensus sequence of collagens.
    Metlas R; Skerl V; Pongor S; Colombatti A; Veljković V
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1425-6. PubMed ID: 7888196
    [No Abstract]   [Full Text] [Related]  

  • 52. HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection.
    Basu D; Kraft CS; Murphy MK; Campbell PJ; Yu T; Hraber PT; Irene C; Pinter A; Chomba E; Mulenga J; Kilembe W; Allen SA; Derdeyn CA; Hunter E
    Retrovirology; 2012 Sep; 9():76. PubMed ID: 22995123
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection.
    Lizeng Q; Skott P; Sourial S; Nilsson C; Andersson S S; Ehnlund M; Taveira N; Björling E
    Virology; 2003 Apr; 308(2):225-32. PubMed ID: 12706073
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characteristics of IgA antibodies against HIV-1 in sera and saliva from HIV-seropositive individuals in different clinical stages.
    Matsuda S; Oka S; Honda M; Takebe Y; Takemori T
    Scand J Immunol; 1993 Nov; 38(5):428-34. PubMed ID: 8235446
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients.
    Borrego P; Marcelino JM; Rocha C; Doroana M; Antunes F; Maltez F; Gomes P; Novo C; Barroso H; Taveira N
    Retrovirology; 2008 Sep; 5():78. PubMed ID: 18778482
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characteristics of IgA anti-HIV antibodies in plasma from patients with HIV infection.
    Matsuda S; Noda M; Toyota A; Tokumoto S; Miyata M
    Microbiol Immunol; 1997; 41(10):785-90. PubMed ID: 9403502
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities.
    Seaton KE; Ballweber L; Lan A; Donathan M; Hughes S; Vojtech L; Moody MA; Liao HX; Haynes BF; Galloway CG; Richardson BA; Karim SA; Dezzutti CS; McElrath MJ; Tomaras GD; Hladik F
    PLoS One; 2014; 9(7):e101863. PubMed ID: 25054205
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detection of IgA inhibiting the interaction between gp120 and soluble CD4 receptor in serum and saliva of HIV-1-infected patients.
    Vincent N; Malvoisin E; Pozzetto B; Lucht F; Genin C
    AIDS; 2004 Jan; 18(1):37-43. PubMed ID: 15090827
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Isotypes and IgG subclasses of anti-Fab antibodies in human immunodeficiency virus-infected hemophilia patients.
    Süsal C; Oberg HH; Daniel V; Dörr C; Terness P; Huth-Kühne A; Zimmermann R; Opelz G
    Vox Sang; 1994; 66(1):37-45. PubMed ID: 7908473
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quantitation of HIV-1-specific IgG, IgA, and IgM antibodies in human genital tract secretions.
    Haimovici F; Mayer KH; Anderson DJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Jul; 15(3):185-91. PubMed ID: 9257652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.